Latest News

1789 items found, showing page 7 of 150

Scottish Enterprise logo

Cash boost for health and finance research schemes

PROJECTS putting Scotland at the forefront of the fintech and life sciences sectors have been awarded funding of  £146m. 

Reactec Safedistance 2 (small)

Fundraising round supports Scottish developer of social distancing tech

Reactec, the Edinburgh-based tech company that recently launched its innovative SAFE-DISTANCE device to enable social distancing among workers, has completed a further £700,000 round of fundraising for the ongoing development of its innovative personal monitoring equipment and reporting technology.

Symbiosis Stirling (small)

Symbiosis and AstraZeneca sign supply agreement for sterile manufacture of COVID-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.

Steve Dunlop BSFT-009

Scottish Enterprise Welcomes COVID-19 Economic Recovery Report

A report by an independent group of experts looking at future economic growth in response to the coronavirus pandemic has been welcomed by Scottish Enterprise.

Lochaline Harbour, Morvern Gloo

Lochaber community hydropower scheme confirms new finance

The Morvern Community Development Company (MCDC) has worked with Triodos Bank UK and the Scottish Investment Bank (SIB), the investment arm of Scottish Enterprise, to secure a new finance arrangement to support the development of a high-head (142m) hydropower scheme on the Barr River near Loch Teacuis, Morvern in Lochaber, Scotland.

Isabella Miller SfEO

Industry Leadership Group ‘Scotland for Employee Ownership’ announces appointment of new Co-Chair

  • Head of John Lewis Glasgow Isabella Miller confirmed for highly-coveted role
  • John Lewis Partnership is largest employee-owned business in the UK
  • Scotland for Employee Ownership has aspiration of 500 employee-owned businesses by 2030
Trojan Energy

Widespread electric vehicle use boosted by £4.1m deal for new on-street charging solution

The widespread use of electric vehicles across the UK has moved a step closer following a £4.1 million funding deal to support the growth of Trojan Energy’s innovative on-street charging product.

Scottish Enterprise logo

Clyde Space embarks on next generation satellite project with Scottish Enterprise support

AAC Clyde Space, the Glasgow-based space solutions company, has announced it has begun development of its next generation of nano and small satellites with support from Scottish Enterprise.

MPA-6

Edinburgh software firm ION Geo aims to make ports smarter, safer and greener, starting in Montrose

ION Geo is a global software firm with a base in Edinburgh and has transformed manual operations at Montrose Port Authority with its Marlin™ SmartPort optimisation software and recently completed a full digital switchover.

Glasgow View

Importance of FDI to COVID-19 recovery underlined by latest EY Attractiveness Survey

Scottish Enterprise has welcomed the publication of EY Scotland’s Attractiveness Survey 2020 that confirms Scotland continues to be the most attractive location for inward investment in the UK outside of London.

Pneumagen-image

Pneumagen announces £4m fundraising and commits to clinical trial development for COVID-19

Pneumagen (Holdings) Ltd, focused on treating infectious diseases by targeting the human glycome, today announced a GBP £4 million investment to allow the clinical development of Neumifil for the prevention and treatment of COVID-19.

Scottish Enterprise logo

MGB Biopharma announces successful outcome from Phase II clinical study on MGB-BP-3 for the treatment of Clostridium difficile Infection

MGB Biopharma, the Glasgow-based biopharmaceutical company developing a novel class of anti-infectives, today announced the successful conclusion of its Phase II clinical study into MGB-BP-3, for the treatment of Clostridium difficile Infection (CDI). The study confirms that the drug has the potential to become the new gold standard, first-line treatment for CDI.